Kidney Week

Abstract: TH-PO1031

Effectiveness of Sucroferric Oxyhydroxide (SO) in Lowering Serum Phosphorus (sP) in 4,925 Chronic Hemodialysis (HD) Patients Prescribed SO as Part of Routine Care

Session Information

• Mineral Disease: Ca/Mg/PO4
  November 02, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

• 1201 Mineral Disease: Ca/Mg/PO4

Authors

• Coyne, Daniel W., Washington University School of Medicine, St. Louis, Missouri, United States

Daniel W. Coyne,

• Ficociello, Linda H., Fresenius Medical Care North America, Waltham, Massachusetts, United States

Linda H. Ficociello,

• Parameswaran, Vidhya, Fresenius Medical Care North America, Waltham, Massachusetts, United States

Vidhya Parameswaran,

• Ofsthun, Norma J., Fresenius Medical Care North America, Waltham, Massachusetts, United States

Norma J. Ofsthun,

• Mullon, Claudy, Fresenius Medical Care North America, Waltham, Massachusetts, United States

Claudy Mullon,

• Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States

Robert J. Kossmann,

• Sprague, Stuart M., NorthShore University HealthSystem University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States

Stuart M. Sprague,

Background

Although the majority of HD patients are prescribed phosphate binders (PB), hyperphosphatemia is highly prevalent. A barrier to phosphorus control can be the high pill burden of most PB. The current analysis aimed to assess the effectiveness of SO in lowering sP and PB pill burden in a large patient population.

Methods

Patients included in the analysis were all Fresenius Kidney Care (FKC) patients switched during 1/1/14 -12/31/16 from PB monotherapy to SO monotherapy for at least three months. Baseline was defined as the 3 months before SO, when prior PB was used. Patients were followed until end of analysis period, end of monotherapy SO, or discharge from FKC. Mean prescribed PB pills/day and sP levels were calculated using mixed effects linear regression. In-range sP was defined as sP ≤ 5.5 mg/dl.

Results

Patients (n=4925) had a mean age of 55 years and dialysis vintage of 53 months. During baseline the majority of patients were hyperphosphatemic (only 18.9% had sP ≤ 5.5 mg/dl). Achievement of sP ≤ 5.5 mg/dl improved over SO from 28.5% at Q1 to 41% at Q8. Patients were prescribed, on average, 9.5 pills/day and this was reduced by >50% (4.2 to 4.7 pills/day) during SO follow-up. At baseline, patients were treated with sevelamer (Sev), calcium acetate (CaAc), ferric citrate (FC), or lanthanum carbonate (LC). Figures demonstrate the increases in patients achieving sP ≤ 5.5 mg/dl by the 4 baseline PB.

Conclusion

In a large cohort of patients switching to SO, improvements in achieving sP ≤ 5.5 mg/dl were observed across all baseline PB.

Funding

• Commercial Support –